| scholarly article | Q13442814 |
| P2093 | author name string | P G Kremsner | |
| J Horton | |||
| M A Missinou | |||
| J F Faucher | |||
| B Lell | |||
| S Borrmann | |||
| O Dangelmaier | |||
| P2860 | cites work | Prophylaxis of Plasmodium falciparum infection in a human challenge model with WR 238605, a new 8-aminoquinoline antimalarial. | Q33696465 |
| Malaria control in Nicaragua: social and political influences on disease transmission and control activities | Q33870147 | ||
| Randomised placebo-controlled trial of primaquine for prophylaxis of falciparum and vivax malaria. | Q34288516 | ||
| The presentation, management and prevention of crisis in sickle cell disease in Africa | Q38617805 | ||
| The role of red blood cell polymorphisms in resistance and susceptibility to malaria | Q39170290 | ||
| Randomised placebo-controlled study of atovaquone plus proguanil for malaria prophylaxis in children | Q39170296 | ||
| Randomised placebo-controlled trial of iron supplementation and malaria chemoprophylaxis for prevention of severe anaemia and malaria in Tanzanian infants | Q39244633 | ||
| Randomized dose-ranging study of the safety and efficacy of WR 238605 (Tafenoquine) in the prevention of relapse of Plasmodium vivax malaria in Thailand | Q41923249 | ||
| Daily primaquine is effective for prophylaxis against falciparum malaria in Kenya: comparison with mefloquine, doxycycline, and chloroquine plus proguanil | Q41932952 | ||
| Mefloquine compared with other malaria chemoprophylactic regimens in tourists visiting east Africa. | Q41937668 | ||
| Epidemic of malaria in north-eastern Kenya | Q44023064 | ||
| First-time-in-humans safety and pharmacokinetics of WR 238605, a new antimalarial. | Q47831031 | ||
| The distribution of birth weights in Gambian women who received malaria chemoprophylaxis during their first pregnancy and in control women | Q48010763 | ||
| Confidence limits on the ratio of two Poisson variables | Q68788751 | ||
| P433 | issue | 9220 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | malaria | Q12156 |
| P304 | page(s) | 2041-5 | |
| P577 | publication date | 2000-06-10 | |
| P1433 | published in | The Lancet | Q939416 |
| P1476 | title | Malaria chemoprophylaxis with tafenoquine: a randomised study | |
| P478 | volume | 355 |
| Q28204425 | A new primaquine analogue, tafenoquine (WR 238605), for prophylaxis against Plasmodium falciparum malaria |
| Q48015887 | A randomized, double-blind, active-control trial to evaluate the efficacy and safety of a three day course of tafenoquine monotherapy for the treatment of Plasmodium vivax malaria |
| Q34456807 | Antimalarial compounds in Phase II clinical development. |
| Q35541777 | Antimalarial drug discovery: old and new approaches |
| Q36196479 | Antimalarial drugs: current status and new developments |
| Q38573032 | Antimicrobial prevention and therapy for travelers' infection. |
| Q58828760 | Antiprotozoal drugs |
| Q58828766 | Antiprotozoal drugs |
| Q36322092 | Atovaquone/proguanil for the prophylaxis and treatment of malaria |
| Q44413957 | Blood schizontocidal activity of WR 238605 (Tafenoquine) against Plasmodium cynomolgi and Plasmodium fragile infections in rhesus monkeys |
| Q43752867 | Causal prophylactic efficacy of atovaquone-proguanil (Malarone) in a human challenge model |
| Q24243240 | Chemoprophylaxis and intermittent treatment for preventing malaria in children |
| Q24245420 | Chemoprophylaxis and intermittent treatment for preventing malaria in children |
| Q37052790 | Clinical development of new prophylactic antimalarial drugs after the 5th Amendment to the Declaration of Helsinki |
| Q64056980 | Clinical utility of tafenoquine in the prevention of relapse of malaria: a review on the mode of action and emerging trial data |
| Q34843970 | Clinical, environmental, and serologic surveillance studies of melioidosis in Gabon, 2012-2013 |
| Q33732727 | DSM265 for Plasmodium falciparum chemoprophylaxis: a randomised, double blinded, phase 1 trial with controlled human malaria infection |
| Q34597823 | Effect of fluorescent dyes on in vitro-differentiated, late-stage Plasmodium falciparum gametocytes |
| Q38027179 | Emerging drugs for malaria |
| Q48031961 | Gender differences in gastrointestinal disturbances and plasma concentrations of tafenoquine in healthy volunteers after tafenoquine administration for post-exposure vivax malaria prophylaxis |
| Q39381315 | History and perspectives of medical research at the Albert Schweitzer Hospital in Lambaréné, Gabon |
| Q43152251 | In vitro activity of tafenoquine against the asexual blood stages of Plasmodium falciparum isolates from Gabon, Senegal, and Djibouti |
| Q21032527 | Intermittent preventive treatment for malaria in children living in areas with seasonal transmission |
| Q26799721 | Malaria Diagnosis Across the International Centers of Excellence for Malaria Research: Platforms, Performance, and Standardization |
| Q58214241 | Malaria and Travellers |
| Q30994453 | Malaria chemoprophylaxis in the age of drug resistance. II. Drugs that may be available in the future |
| Q44430520 | Malaria prevention in international travel |
| Q39096704 | Medical research at the Albert Schweitzer Hospital |
| Q36286204 | Modern malaria chemoprophylaxis |
| Q35581916 | New Antimalarial Drugs |
| Q38148787 | Novel approaches in antimalarial drug discovery |
| Q37353434 | Pharmacokinetic interactions and safety evaluations of coadministered tafenoquine and chloroquine in healthy subjects |
| Q38129536 | Plasmodium falciparum gametocytes: with a view to a kill. |
| Q35912649 | Population pharmacokinetics of tafenoquine during malaria prophylaxis in healthy subjects |
| Q44147117 | Prevention of malaria in children |
| Q36406218 | Problem pathogens: prevention of malaria in travellers |
| Q44150527 | Problems in prescribing malaria chemoprophylaxis for travelers |
| Q33613720 | Randomized, double-blind study of the safety, tolerability, and efficacy of tafenoquine versus mefloquine for malaria prophylaxis in nonimmune subjects |
| Q35147242 | Safety, efficacy and determinants of effectiveness of antimalarial drugs during pregnancy: implications for prevention programmes in Plasmodium falciparum-endemic sub-Saharan Africa |
| Q38245842 | Strategic use of antimalarial drugs that block falciparum malaria parasite transmission to mosquitoes to achieve local malaria elimination |
| Q26741307 | Tafenoquine and its potential in the treatment and relapse prevention of Plasmodium vivax malaria: the evidence to date |
| Q34811224 | Tafenoquine at therapeutic concentrations does not prolong Fridericia-corrected QT interval in healthy subjects |
| Q24186356 | Tafenoquine for preventing relapse in people with Plasmodium vivax malaria |
| Q58089503 | Tafenoquine for travelers' malaria: evidence, rationale and recommendations |
| Q92297877 | Tafenoquine succinate for malaria prevention |
| Q36802630 | Tafenoquine: a promising new antimalarial agent |
| Q36320249 | The global pipeline of new medicines for the control and elimination of malaria |
| Q47938411 | Tropical medicine at the University of Tübingen |
Search more.